Medigen Biotechnology Corp. announced Taiwan Mohw Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by the Company and Wanfang Hospital. Medigen, in collaboration with Taipei Municipal Wanfang Hospital managed by Taipei Medical University (referred to as Wanfang Hospital), has applied to the Ministry of Health and Welfare (MOHW) on January 22, 2024, for a new version of the Autologous Natural Killer (Magicell-NK) cell therapy project for treating stage IV solid tumors in accordance with the regulations of the ?Regulations Governing the Application of Specific Medical Examination Technique and Medical Device?.

On June 6, 2024, Medigen received the approval letter from the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice (GTP). Details on the approved items in the abovementioned Wanfang Hospital cell therapy project: (1)Type of Cell Therapy: Autologous natural killer cells (NK cells) - Magicell-NK. (2) Indications: Stage IV solid tumors, including Brain cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, liver cancer, bile duct cancer, pancreatic cancer, prostate cancer, colorectal cancer.

(3) Cell Processing Unit: Medigen?s cell processing unit (4)Validity Period: From June 4, 2024, to February 2, 2026.